Capricor Therapeutics, INC 10-Q quarterly reports

Capricor Therapeutics has filed a lawsuit against Nippon Shinyaku alleging material breaches of their U.S. distribution agreement for Deramiocel.

Capricor Therapeutics received a Complete Response Letter from the FDA for its Deramiocel BLA, requiring additional clinical data, while reporting significantly increased net losses for the nine months ended September 30, 2025.

Capricor Therapeutics reported a significantly wider net loss in Q2 2025 and received a Complete Response Letter from the FDA for its Duchenne muscular dystrophy therapy, deramiocel, requiring additional clinical data.

Capricor Therapeutics announces Q1 2025 financial results and provides an update on its BLA submission for deramiocel, which has been granted Priority Review by the FDA.

Capricor Therapeutics reports a net loss of $12.6 million for the third quarter of 2024, while highlighting progress in its clinical programs and strategic partnerships.

Capricor Therapeutics reported its second quarter 2024 financial results, highlighting progress in its Duchenne muscular dystrophy program and exosome platform development.

Capricor Therapeutics reports a net loss of $9.8 million for the first quarter of 2024, while highlighting progress in its clinical programs and exosome platform.